ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Tyrosine kinase inhibitors, including imatinib, dasatinib, and nilotinib, have revolutionized CML treatment by specifically targeting the BCR-ABL oncoprotein, thereby controlling disease progression and reducing the hematopoietic burden.